J. Safra Sarasin Holding AG purchased a new position in shares of Centene Corporation (NYSE:CNC – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 27,149 shares of the company’s stock, valued at approximately $1,117,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mn Services Vermogensbeheer B.V. raised its stake in Centene by 1.3% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 187,981 shares of the company’s stock worth $7,735,000 after acquiring an additional 2,481 shares in the last quarter. Northwest Wealth Management LLC bought a new stake in shares of Centene during the fourth quarter worth $674,000. Kaufman Rossin Wealth LLC increased its holdings in shares of Centene by 98.5% during the fourth quarter. Kaufman Rossin Wealth LLC now owns 20,419 shares of the company’s stock worth $840,000 after buying an additional 10,131 shares in the last quarter. Pallas Capital Advisors LLC lifted its stake in shares of Centene by 126.4% in the 4th quarter. Pallas Capital Advisors LLC now owns 146,439 shares of the company’s stock valued at $6,026,000 after acquiring an additional 81,749 shares during the last quarter. Finally, Family Wealth Partners LLC acquired a new stake in shares of Centene during the 4th quarter valued at $295,000. Institutional investors own 93.63% of the company’s stock.
Centene Price Performance
Shares of NYSE CNC opened at $33.99 on Thursday. The firm has a market capitalization of $16.71 billion, a P/E ratio of -2.50, a P/E/G ratio of 0.72 and a beta of 0.59. The firm’s 50-day moving average price is $39.62 and its 200-day moving average price is $38.72. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.87. Centene Corporation has a 1-year low of $25.08 and a 1-year high of $66.03.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on CNC. Wall Street Zen cut Centene from a “buy” rating to a “hold” rating in a report on Sunday, February 15th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $41.00 target price on shares of Centene in a report on Monday, February 9th. TD Cowen upped their price target on Centene from $34.00 to $38.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Sanford C. Bernstein restated an “outperform” rating and set a $59.00 price objective on shares of Centene in a research report on Tuesday, January 6th. Finally, Truist Financial lifted their price objective on Centene from $47.00 to $49.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Three equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $41.81.
Check Out Our Latest Stock Report on CNC
About Centene
Centene Corporation (NYSE: CNC) is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children’s Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.
Centene’s offerings extend beyond traditional insurance to include a range of specialty and support services.
Featured Stories
Want to see what other hedge funds are holding CNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Centene Corporation (NYSE:CNC – Free Report).
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.
